To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Latest action
- Jul 20, 2026
What it does
This bill would amend the Federal Food, Drug, and Cosmetic Act to create a new pathway for expedited approval of certain nonprescription (over-the-counter) drugs designated as "priority nonprescription drugs" by the Secretary of Health and Human Services. It affects drug sponsors seeking approval for nonprescription drugs that meet specific criteria, such as being intended for a novel nonprescription indication with meaningful public health benefit, being a new molecular entity, or containing an active ingredient never before available nonprescription. The bill requires the Secretary to make designation decisions within 60 days of a request, take actions to facilitate development and review…
AI summary · The lawmakers haven’t published an official summary of this bill yet, so 52 wrote this one from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.